Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Andes, David R, Ghannoum, Mahmoud A, Mukherjee, Pranab K, Kovanda, Laura L ORCID: 0000-0002-4493-4652, Lu, Qiaoyang, Jones, Mark E, Henriksen, Anne Santerre, Lademacher, Christopher and Hope, William W ORCID: 0000-0001-6187-878X (2019) Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63 (1). e01634-e01618.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1128/aac.01634-18

Abstract

This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of <i>Aspergillus</i> pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.

Item Type:	Article
Uncontrolled Keywords:	MIC, clinical trial, isavuconazole, isavuconazonium sulfate, voriconazole
Depositing User:	Symplectic Admin
Date Deposited:	17 Jan 2019 11:12
Last Modified:	07 Feb 2024 15:35
DOI:	10.1128/AAC.01634-18
Open Access URL:	https://aac.asm.org/content/63/1/e01634-18
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3031429